The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: A randomized double-blind crossover trial

Journal of Cardiovascular Pharmacology

Volumn 52, Issue 2, 2008, Pages 145-150

  Olijhoek, Jobien K ^a   Hajer, Gideon R ^a   Graaf, Yolanda Van Der ^a   Dallinga Thie, Geesje M ^b   Visseren, Frank L J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Endothelial function; Ezetimibe; Metabolic syndrome; Postprandial lipid profiles; Statins

Indexed keywords

APOLIPOPROTEIN B; EZETIMIBE; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL; AZETIDINE DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGED; ARTERY DILATATION; ARTICLE; BLOOD LEVEL; BODY FAT; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG MEGADOSE; ENDOTHELIUM CELL; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LOW DRUG DOSE; MALE; METABOLIC SYNDROME X; MONOTHERAPY; OBESITY; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; ADOLESCENT; BLOOD; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; FAT INTAKE; HYPERCHOLESTEROLEMIA; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; VASCULAR ENDOTHELIUM;

ADOLESCENT; ADULT; AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DIETARY FATS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; HUMANS; HYPERCHOLESTEROLEMIA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POSTPRANDIAL PERIOD; PROSPECTIVE STUDIES; SIMVASTATIN; TRIGLYCERIDES;

EID: 56149091842     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31817ffe76     Document Type: Article

References (31)

1. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
2. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;40:2125-2134.
3. Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet. 1995;346:467-471.
4. John S, Schlaich M, Langenfeld M, et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation. 1998; 98:211-216.
5. Ceriello A, Taboga C, Tonutti L, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short-and long-term simvastatin treatment. Circulation. 2002;106:1211-1218.
6. Evans M, Anderson RA, Graham J, et al. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation. 2000;101:1773-1779.
7. Grieve DJ, Avella MA, Elliott J, et al. The influence of chylomicron remnants on endothelial cell function in the isolated perfused rat aorta. Atherosclerosis. 1998;139:273-281.
8. Kugiyama K, Doi H, Motoyama T, et al. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation. 1998;97:2519-2526.
9. Funada J, Sekiya M, Otani T, et al. The close relationship between postprandial remnant metabolism and insulin resistance. Atherosclerosis. 2004;172:151-154.
10. Johanson EH, Jansson PA, Gustafson B, et al. Early alterations in the postprandial VLDL1 apoB-100 and apoB-48 metabolism in men with strong heredity for type 2 diabetes. J Intern Med. 2004;255:273-279.
11. Baron AD. Vascular reactivity. Am J Cardiol. 1999;84:25-27.
12. Wheatcroft SB, Williams IL, Shah AM, et al. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med. 2003;20:255-268.
13. Hulthe J, Hulten LM, Fagerberg B. Low adipocyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: atherosclerosis and insulin resistance study. Metabolism. 2003;52:1612-1614.
14. Tan KC, Xu A, Chow WS, et al. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab. 2004;89:765-769.
15. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
16. Kamalesh M, Rao R, Sawada S, et al. Effect of 80 mg/day simvastatin therapy on cardiovascular outcomes in adults with versus without metabolic syndrome. Am J Cardiol. 2006;97:1487-1489.
17. Martens FM, Visseren FL, de Koning EJ, et al. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovac Pharmacol. 2005;46:773-778.
18. Twickler TB, Dallinga-Thie GM, Visseren FL, et al. Induction of postprandial inflammatory response in adult onset growth hormone deficiency is related to plasma remnant-like particle-cholesterol concentration. J Clin Endocrinol Metab. 2003;88:1228-1233.
19. Pocock SJ.Clinical Trials: A Practical Approach. Chichester, UK: John Wiley & Sons; 1983.
20. Kosoglou T, Statkevich P, Johnson-Levonas AO, et al. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44:467-494.
21. Altmann SW, Davis HR, Jr., Zhu LJ, et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303:1201- 1204.
22. Tremblay AJ, Lamarche B, Cohn JS, et al. Effect of ezetimibe on the in vivo kinetics of ApoB-48 and ApoB-100 in men with primary hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2006;26:1101-1106.
23. de Graaf J, van der Vleuten GM, ter Avest E, et al. High plasma level of remnant-like particles cholesterol in familial combined hyperlipidemia. J Clin Endocrinol Metab. 2007;92:1269-1275.
24. Sager PT, Capece R, Lipka L, et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholes- terolemic patients. Atherosclerosis. 2005;179:361-367.
25. Bataille R, Klein B. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum. 1992;35:982-984.
26. Huptas S, Geiss HC, Otto C, et al. Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome. Am J Cardiol. 2006;98:66-69.
27. Hulthe J, Bokemark L, Wikstrand J, et al. The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study. Arterioscler Thromb Vasc Biol. 2000;20:2140-2147.
28. Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation. 2005;111:2356-2363.
29. Fichtlscherer S, Schmidt-Lucke C, Bojunga S, et al. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. Eur Heart J. 2006;27:1182-1190.
30. Maggi FM, Raselli S, Grigore L, et al. Lipoprotein remnants and endothelial dysfunction in the postprandial phase. J Clin Endocrinol Metab. 2004;89:2946-2950.
31. Bulut D, Hanefeld C, Bulut-Streich N, et al. Endothelial function in the forearm circulation of patients with the metabolic syndrome-effect of different lipid-lowering regimens. Cardiology. 2005;104:176-180.